A $2 Billion Bet on a Drug That Hasn't Touched a Human Yet

Why Pharma Is Paying Up for Preclinical Assets

A $2 billion deal for a preclinical asset sounds insane until you zoom out and look at what's happening across the industry.

In 2024, Roche poured over $1 billion into preclinical-stage assets across three separate deals. Novartis paid $1 billion upfront for PTC Therapeutics' midphase Huntington's disease program. Merck committed up to $1.9 billion for a preclinical GLP-1 agonist from Hansoh Pharma, with just $112 million upfront.

The pattern is clear: big pharma is buying earlier and paying more. Patent cliffs are looming. Blockbuster drugs are losing exclusivity. And the companies with the deepest pockets would rather overpay for a shot at the next generation of medicines than watch from the sidelines.

BeOne's deal fits this playbook perfectly. The $20 million upfront is a rounding error on their balance sheet; it's essentially paying for a seat at the table. The real money only flows if HH160 proves itself.

The Trispecific Gold Rush

HH160 doesn't exist in a vacuum. The multispecific antibody space is exploding, with over 700 multispecific antibodies in clinical trials.

But here's what's fascinating: no trispecific antibody has been approved yet. The field is wide open.

Janssen is running Phase 1 trials for JNJ-79635322, a trispecific targeting BCMA, GPRC5D, and CD3 in multiple myeloma. Ichnos Sciences, Suzhou Zelgen, and Sanofi all have early-stage trispecific programs. In March 2026, Sanofi signed a $1.23 billion deal with Kali Therapeutics for KT501, another trispecific (this one for autoimmune diseases).

The thesis is straightforward: if bispecifics were an upgrade over single-target antibodies, trispecifics could be another leap forward. More targets means more precision, potentially better efficacy, and (if designed well) fewer off-target effects.

BeOne's Bigger Game

This isn't BeOne's first trispecific rodeo. The company already has BG-T187 in Phase 1 trials, targeting EGFR and c-Met (with a biparatopic design, meaning it binds c-Met at two different spots) for lung cancer and solid tumors. HH160 gives them a second trispecific asset with a completely different mechanism: immune checkpoint blockade plus anti-angiogenesis rather than receptor tyrosine kinase inhibition.

BeOne is essentially building a trispecific antibody portfolio, covering both direct tumor targeting and immune system activation. That's a strategic bet that this technology class will define the next decade of cancer treatment.

The Option Structure Is the Smart Part

Let's not overlook the deal structure. BeOne didn't buy HH160 outright. They bought an option on it. For $20 million, they get to watch the data develop and decide later whether to spend $100 million for the full license. If preclinical work goes sideways, they walk away having spent less than most companies spend on a single clinical trial.

It's like putting down a deposit on a house you can inspect before closing. The $1.9 billion in milestones? Those only trigger if the drug actually hits specific development, regulatory, and commercial targets. BeOne is paying for performance, not promises.

The Big Question

The multispecific antibody space is moving fast. Chinese biotechs accounted for about 25% of multispecific deals in the past year, generating more than $2.6 billion in upfront payments across ten transactions. The technology is maturing. Manufacturing challenges that once seemed insurmountable are being solved by platforms like PolyBoost.

But trispecifics remain unproven in patients. The preclinical data for HH160 looks promising on paper: synergistic anti-tumor effects, lower cytokine release, simplified dosing compared to combination regimens. Whether any of that translates to real clinical benefit is still an open question.

Two billion dollars says BeOne believes the answer is yes. Now they just need biology to cooperate.

GSK Bet $700M on a Brain Theory. It Just Lost Twice.

GSK and Alector just killed their second Alzheimer's trial in six months, effectively torching a $700 million partnership. The failure raises uncomfortable questions about whether targeting the brain's immune system can actually slow neurodegeneration.